ReviR Therapeutics, a biopharmaceutical firm focused on the development of ribonucleic acid (RNA) targeting small molecule therapies that modulate the causal genes of diseases, has snapped up $30 million in a Series A financing round.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
